Bernstein initiated coverage of Novo Nordisk (NVO) with an Underperform rating and DKK 175 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Ramps Up 2026 Share Buy‑Back, Holding 0.5% of Capital as Treasury Stock
- Novo Nordisk price target lowered to DKK 280 from DKK 350 at HSBC
- Structure’s GLP-1 pill could put company on M&A radar, Barron’s says
- Hims, Novo, CrowdStrike, SolarEdge, Telus Trending With Analysts
- Novo Nordisk price target lowered to DKK 300 from DKK 360 at Berenberg